OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer
Opthea Recruits 176th Patient and On-Track to Report Primary Data Analysis Early 2020
OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a...
Continue Reading →
